SCHEDULE: Intracoastal Capital Reports Zero Stake in AIM ImmunoTech

Reporting persons Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC have disclosed a zero percent beneficial ownership stake in AIM ImmunoTech Inc. as of May 27, 2026.

Summary

• The filing confirms that as of May 27, 2026, the reporting persons (Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC) hold zero shares of AIM ImmunoTech Inc. common stock.
• The disclosure follows a previous Securities Purchase Agreement (SPA) dated May 20, 2026, which initially contemplated the issuance of 1,538,462 shares to Intracoastal Capital.
• The reporting persons hold warrants for 3,076,924 shares, but these are currently not exercisable due to a 4.99% ownership blocker provision and the requirement for prior stockholder approval.
• The filing serves as a formal notification that the reporting persons do not currently meet the 5% threshold for beneficial ownership.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory filing. It confirms the current lack of active beneficial ownership by the reporting group while acknowledging the existence of potential future equity issuance via warrants.

Positives

• The filing provides transparency regarding the current ownership status of significant institutional investors.
• The inclusion of a 4.99% blocker provision on warrants protects existing shareholders from immediate dilution.

Negatives

• The reporting persons have reduced their beneficial ownership to zero, which may signal a change in investment strategy or divestment regarding the issuer.

Risks

• Potential future dilution exists if the 3,076,924 shares underlying the Intracoastal Warrant are issued following stockholder approval.
• The exercise of warrants is contingent upon regulatory and shareholder approvals, creating uncertainty regarding the timing and impact of potential share issuance.

Future Outlook

The reporting persons hold warrants that are not currently exercisable. Future ownership levels depend on the receipt of stockholder approval for the issuance of shares underlying these warrants and the removal of the 4.99% blocker provision.

Industry Context

StockSavvy.ai notes that this filing is a standard regulatory disclosure for institutional investors. The use of 'blocker provisions' in warrants is a common mechanism in biotech financing to manage ownership thresholds and avoid triggering change-of-control provisions or excessive dilution.

Comparison to Industry Standards

• The disclosure follows standard SEC Schedule 13G requirements for reporting beneficial ownership.
• The use of 4.99% ownership blockers is consistent with standard practices in small-cap biotechnology private placements to maintain compliance with exchange rules and investor mandates.

Stakeholder Impact

• Existing shareholders should monitor the potential for future dilution if the warrants become exercisable.
• The lack of current beneficial ownership by the reporting group suggests no immediate influence on corporate governance by these specific investors.

Next Steps

• Potential stockholder vote to approve the issuance of shares underlying the Intracoastal Warrant.
• Future filings if the reporting persons acquire or dispose of shares exceeding the 5% threshold.

Key Dates

Keywords

AIM ImmunoTech, Schedule 13G, Intracoastal Capital, Beneficial Ownership, Common Stock, Warrants, SEC Filing